Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib and Belinostat in Relapsed/Refractory Aggressive Lymphomas
NCT02875002Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volasertib in B cell lymphoma and T-cell lymphoma, sponsored by Yale University. Primary endpoints: Maximum Tolerated Dose at 2 years and Adverse Events at 2 years. Planned start Oct 2016; status: withdrawn.
02
Drugs
volasertib
03
Conditions
B cell lymphomaT-cell lymphoma
Beyond the preview
Go deeper on NCT02875002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875002.